1. Yasuda I, Hasegawa K, Sakamaki Y, Muraoka H, Kawaguchi T, Kusahana E, Ono T, Kanda T, Tokuyama H, Wakino S, Itoh H. Pre-emptive short-term nicotinamide mononucleotide treatment in a mouse model of diabetic nephropathy. J Am Soc Nephrol. 2021 Apr 1. doi: 10.1681/ASN.2020081188.
2. Nakamichi R, Hayashi K, Itoh H. Effects of high glucose and lipotoxicity on diabetic podocytes. Nutrients. 13:241, 2021.
3. Kawaguchi T, Hasegawa K, Yasuda I, Muraoka H, Umino H, Tokuyama H, Hashiguchi A, Wakino S, Itoh H. Diabetic condition induces hypertrophy and vacuolization in glomerular parietal epithelial cells. Sci Rep. 11:1515, 2021.
4. Amiya T, Nakamoto N, Irie J, Taniki N, Chu PS, Koda Y, Miyamoto K, Yamaguchi A, Shiba S, Morikawa R, Itoh H, Kanai T. C-C motif chemokine receptor 9 regulates obesity-induced insulin resistance via inflammation of the small intestine in mice. Diabetologia. 64:603-617, 2021.
5. Meguro S, Inaishi J, Sato Y, Komuro I, Itoh H. One-year estimated glomerular filtration rate decline as a risk factor of cardiovascular and renal end-points in high-risk Japanese patients. J Diabetes Investig. 2020 Dec 4. doi: 10.1111/jdi.13474.
6. Nakayama T, Uchiyama K, Naoki N, Morimoto K, Muraoka K, Adachi K, Kasai T, Miyashita K, Wakino S, Itoh H. Exercise parameters predict technique survival in patients on peritoneal dialysis. Blood Purif. 2020 Oct 22. doi: 10.1159/000511293.
7. Yokota K, Shibata H, Kurihara I, Kobayashi S, Murai-Takeda A, Itoh H. CASZ1b is a novel transcriptional corepressor of mineralocorticoid receptor. Hypertens Res. 44:407-416, 2021.
8. Minakuchi H, Wakino S, Urai H, Kurokochi A, Hasegawa K, Kanda T, Tokuyama H, Itoh H. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial. Sci Rep. 10:16626, 2020.
9. Uchiyama K,Washida N,Morimoto K, Muraoka K, Nakayama T, Adachi K, Kasai T, Miyashita K, Wakino S, Itoh H. Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: A post-hoc analysis of a randomized controlled trial. Ther Apher Dial. 24:668-676, 2020. doi: 10.1111/1744-9987.13481
10. Kusakabe T, Yokota S, Shimizu M, Inoue T, Tanaka M, Ohue-Kitano R, Muranaka K, Yamakage H, Wada H, Hasegawa K, Satoh-Asahara N. Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice. BMJ Open Diabetes Res Care. 2020 Sep;8(1):e001303. doi: 10.1136/bmjdrc-2020-001303.